SUPN Logo

Supernus Pharmaceuticals, Inc. (SUPN) 

NASDAQ
Market Cap
$1.97B
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
728 of 774
Rank in Industry
44 of 47

Largest Insider Buys in Sector

SUPN Stock Price History Chart

SUPN Stock Performance

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The …

Insider Activity of Supernus Pharmaceuticals, Inc.

Over the last 12 months, insiders at Supernus Pharmaceuticals, Inc. have bought $0 and sold $15.17M worth of Supernus Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at Supernus Pharmaceuticals, Inc. have bought $0 and sold $6.45M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 14,400 shares for transaction amount of $379,964 was made by Khattar Jack A. (President, CEO) on 2019‑08‑23.

List of Insider Buy and Sell Transactions, Supernus Pharmaceuticals, Inc.

2024-11-11Saledirector
10,700
0.019%
$36.24$387,768+0.92%
2024-11-08SalePresident, CEO
125,000
0.2259%
$36.29$4.54M+0.03%
2024-11-08Saledirector
8,722
0.0158%
$36.28$316,434+0.03%
2024-11-08Saledirector
10,787
0.0195%
$36.30$391,568+0.03%
2024-11-07SalePresident, CEO
125,000
0.2286%
$36.68$4.58M+0.56%
2024-11-07Saledirector
14,213
0.026%
$36.62$520,480+0.56%
2024-11-07SaleSVP, Quality, GMP, Ops, IT
15,000
0.0277%
$36.98$554,700+0.56%
2024-09-13Saledirector
10,000
0.0183%
$31.33$313,300+6.91%
2024-03-21SaleSr. VP of IP, CSO
14,491
0.0266%
$35.31$511,677-10.80%
2024-03-20SaleSr. VP of IP, CSO
400
0.0007%
$35.31$14,124-9.92%
2024-03-19SaleSr. VP of IP, CSO
12,364
0.0227%
$35.31$436,573-10.60%
2024-03-13SaleSr. VP of IP, CSO
62,366
0.1107%
$33.74$2.1M-9.23%
2024-03-12SaleSr. VP of IP, CSO
3,884
0.0071%
$32.99$128,133-4.40%
2024-02-26SaleSr. VP of IP, CSO
5,000
0.0094%
$30.21$151,050+6.34%
2024-01-10SaleSr. V.P., Regulatory Affairs
8,000
0.0146%
$27.91$223,280+9.86%
2023-11-16Saledirector
2,500
0.0046%
$28.01$70,025+6.57%
2023-11-15Saledirector
9,093
0.0166%
$28.50$259,151+4.36%
2023-11-14SaleSVP, Quality, GMP, Ops, IT
1,110
0.002%
$28.13$31,224+5.19%
2023-08-30SaleSr. V.P., Regulatory Affairs
8,100
0.0149%
$32.00$259,200-11.39%
2023-08-25SaleSr. V.P., Regulatory Affairs
5,135
0.0095%
$31.59$162,215-9.81%

Insider Historical Profitability

21.96%
Khattar Jack A.President, CEO
926172
1.6773%
$35.71320+14.22%
NEWHALL CHARLES W IIIdirector
130275
0.2359%
$35.7112+29.48%
Martin Tami TillotsonSr. V.P., Regulatory Affairs
85664
0.1551%
$35.7117+29.48%
Hudson Frederick M.director
28395
0.0514%
$35.7113+29.48%
NEW ENTERPRISE ASSOCIATES 11 LP10 percent owner
10641250
19.2709%
$35.7110+29.48%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$353.46M18.8510.36M-0.2%-$696,321.540.01
The Vanguard Group$211.71M11.296.21M-0.13%-$270,048.87<0.01
Armistice Capital Llc$121.84M6.53.57M-23.18%-$36.77M0.39
Macquarie Group$91.04M4.862.67M-2.51%-$2.34M0.08
Dimensional Fund Advisors$87.22M4.652.56M+4.09%+$3.43M0.02
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.